Gene Therapy Briefs

American Society of Hematology (2013). High-tech advances in gene therapy overcome challenges, offer hope for patients with hard-to-treat blood disorders. Available at www.hematology.org/News/2013/11771.aspx (accessed Jan. 11, 2014 ).

California Institute for Regenerative Medicine (undated). Allogeneic cardiac-derived stem cells for patients following a myocardial infarction, public abstract. Available at www.cirm.ca.gov/our-progress/awards/allogeneic-cardiac-derived-stem-cells-patients-following-myocardial-infarction (accessed Jan. 11, 2014 ).

Capricor Therapeutics (2014). Capricor Therapeutics and Janssen Biotech, Inc. enter into collaboration agreement and exclusive license option. Available at www.irdirect.net/pr/release/id/433460 (accessed Jan. 11, 2014 ).

Celladon (2013). Celladon Corporation announces receipt of EMA scientific advice for MYDICAR® and initiation of AGENT-HF trial. Available at www.celladon.net/media-center/press-release/122-dec-11-2013-celladon-corporation-announces-receipt-of-ema-scientific-advice-for-mydicar-and-initiation-of-agent-hf-tria (Accessed Jan. 11, 2014 ).

Dalzell S. (2013). Memorandum in Trustees of the University of Pennsylvania, plaintiff, v. St. Jude's Children's Research Hospital, defendant, and Juno Therapeutics, intervenor. U.S. District Court, Eastern District of Pennsylvania. Available at http://docs.justia.com/cases/federal/district-courts/pennsylvania/paedce/2:2013cv01502/474741/20/0.pdf (accessed Jan. 11, 2014 ).

Davila M.L. , Riviere I. , Wang X. , et al. (2013). Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy, summarized in abstract #69, 55th Annual Meeting and Exposition of the American Society of Hematology (ASH), held Dec. 7–10 in New Orleans. Available at https://ash.confex.com/ash/2013/webprogram/Paper63026.html. (accessed Jan. 29, 2014 ).

Grupp S.A. , Frey N.V. , Aplenc R. , et. al. (2013). T Cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses, and long-term persistence without Gvhd in children and adults with relapsed, refractory ALL, summarized in Abstract #67, 55th Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 7–10, New Orleans. Available at https://ash.confex.com/ash/2013/webprogram/Paper60913.html (Accessed Jan. 11, 2014 ).

Juno Therapeutics (2013). Counterclaim in Trustees of the University of Pennsylvania, plaintiff, v. St. Jude's Children's Research Hospital, defendant, and Juno Therapeutics, intervenor. Access through PACER, U.S. District Court, Eastern District of Pennsylvania, on Jan. 11, 2014.

Klein F. , Halper-Stromberg A. , Horwitz J.A. , et. al. (2012). HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 492, 118–122.

Novartis (2013). Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia. Available at www.novartis.com/newsroom/media-releases/en/2013/1748415.shtml (accessed Jan. 11, 2014 ).

Penn Medicine (2013). Penn Medicine team reports findings from research study of first 59 adult and pediatric leukemia patients who received investigational, personalized cellular therapy CTL019. Available at www.uphs.upenn.edu/news/News_Releases/2013/12/ctl019/ (accessed Jan. 11, 2014 ).

Porter D.L. , Kalos M. , Frey N.V. , et. al. (2013a). Chimeric antigen receptor modified T cells directed against CD19 (CTL019 Cells) have long-term persistence and induce durable responses in relapsed, refractory CLL, summarized in Abstract #4162, 55th Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 7–10, New Orleans. Available at https://ash.confex.com/ash/2013/webprogram/Paper57239.html (accessed Jan. 11, 2014 ).

Porter D.L. , Kalos M. , Frey N.V. , et. al. (2013b). Randomized phase II doze optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL, summarized in Abstract #873, 55th Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 7–10, New Orleans. Available at https://ash.confex.com/ash/2013/webprogram/Paper57693.html (accessed Jan. 11, 2014 ).

Rockefeller University (2012). Potent antibodies neutralize HIV and could offer new therapy, study finds. Available at http://newswire.rockefeller.edu/2012/11/06/potent-antibodies-neutralize-hiv-and-could-offer-new-therapy-study-finds/ (accessed Jan. 11, 2014).